Navigation Links
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Date:8/19/2007

mportant milestone for us," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "We believe tezampanel has the potential to offer migraine patients an important new treatment option with a novel mechanism of action and we remain on track to announce top line results from the study during the fourth quarter of this year."

In previous clinical trials, tezampanel has been administered to more than 200 healthy adult volunteers or patients. In five Phase IIa, placebo-controlled trials using intravenous administration, tezampanel demonstrated proof of concept in multiple pain models. In one placebo and active-controlled clinical trial in patients with acute migraine, the compound achieved statistical significance in all primary and secondary endpoints traditionally required for regulatory approval. These endpoints included pain relief at two hours, pain-free at two hours and relief of nausea, photophobia and phonophobia.

About AK Receptor Antagonists

AMPA/kainate (AK) receptors are part of the glutamate biological pathway that transmits pain signals to the brain. In addition, these receptors play a critical role in the development of central sensitization phenomena -- a key component of many pain syndromes, including migraine and persistent pain states such as chronic neuropathic pain. AK receptor antagonists selectively bind to certain AK receptors to block transmission of pain signals mediated through the activation of a subtype of glutamate receptors. Because they do not bind to opioid receptors, directly bind to serotonin receptors or constrict blood vessels, the safety profile of AK antagonists may offer important advantages over existing drugs to treat migraine and other chronic pain conditions.

About Migraine

Migraine is a painful neurological condition characterized by an intense and disabling episodic headache. According to the National Headache Foundation, an estimated 30 million people in the U.S. suffer fr
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. ... in China , today announced that it ... ended March 31, 2013, before market on Tuesday, May 28, ... May 28, 2013, at 8:00 a.m. EDT (May 28, 2013 ... financial results and provide an update on recent corporate developments. ...
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., ... on Form S-1 with the U.S. Securities and Exchange ... of its common stock. The number of shares to ... have not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... are acting as joint book-running managers for the offering. ...
(Date:5/16/2013)... WALTHAM, Mass. , May 16, 2013  Alere Inc. ... individuals to take charge of their health at home through ... a cash dividend of $3.00 per share on its Series ... payable on July 15, 2013 to holders of record of ... 1, 2013.  Such payment will cover the amount ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Magnetically Guided Nanoparticles May Deliver Treatments to Human,Organs -, ... and tiny iron-bearing particles to drive healthy cells to,targeted ... may lead to,a new method of delivering cells and ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080107/DC10966 ), The study team, ...
... 7 Fovea Pharmaceuticals SA, which, last,December ... financing, today announced that,its product, Recombinant human ... as Orphan Medicinal Product from the,European Commission, ... for the Evaluation of Medicinal Products (EMEA) ...
Cached Medicine Technology:Researchers Use Magnetism to Target Cells to Animal Arteries 2Researchers Use Magnetism to Target Cells to Animal Arteries 3Researchers Use Magnetism to Target Cells to Animal Arteries 4Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 2Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 3
(Date:5/19/2013)... Angeles (PRWEB) May 19, 2013 Yeast infections ... can appear in sensitive areas of the human body. A ... Yeastrol. This new formula provides a unique method of application ... new spray solution is now provided to men and women ... is naturally absorbed in the body through food and is ...
(Date:5/19/2013)... 2013 Exciting new Skin Brushes are ... a great practice known through the ages but is ... dry body brushing, has so many benefits for our ... Beauty®. "We love that circulation and lymphatic systems get ... the skin, is supported through Skin Brushing." , Why ...
(Date:5/19/2013)... 19, 2013 Beginning Wednesday, May 29 and ... Center (RRVBC) will feature “Hot Dog Wednesdays" and Ice Cold ... will provide hot dogs and all the fixin's to donors ... day throughout the summer. “Donors are our lifeline. The summer ... and adequate blood supply. This is a small way ...
(Date:5/19/2013)... May 19, 2013 The AMTC team will ... the Columbus Georgia Convention & Trade Center on June 1st. ... attend. AMTC auditions are free of charge. , Actors, Models ... for hundreds of successful artists and grads like Caitlin Kinney ... European Tombolini , Chris Young - on his Liquid Neon ...
(Date:5/19/2013)... Minor fender benders and serious car accidents ... to the accident to respond appropriately to the situation. ... (CDC) data from 2010, accidents, including car accidents, are ... fact, in 2005, automobile accident-related deaths cost ... 2.3 million drivers and passengers receive treatment in an ...
Breaking Medicine News(10 mins):Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Actors, Models and Talent for Christ Hosting Auditions in Columbus, GA June 1st in Search of Local Talent 2Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. ... outbreak first linked to tainted cantaloupes has risen to 25, ... 26 states, the U.S. Centers for Disease Control and Prevention ... the cantaloupes in question were recalled in mid-September, more cases ...
... as immunotherapies and targeted therapies that specifically target signaling ... in 20%-50% of cancer patients taking them, which can ... study published Oct. 18 in the Journal ... past two decades, novel antineoplastic agents have been introduced ...
... PROVIDENCE, R.I. [Brown University] A study published online Oct. ... provides some new but qualified support for the idea ... risk of developing deadly brain tumors. People with somewhat ... out the body,s immune response to allergens, were significantly less ...
... LeFevre, MD, Future of Family Medicine Professor and vice ... of Missouri, has been elected to the Institute of ... is considered one of the highest honors in the ... have demonstrated outstanding professional achievement and commitment to service. ...
... & White Healthcare in Temple is one of three sites ... doctoral psychology students that will help alleviate mental health workforce ... a five-year $638,853 grant from the Hogg Foundation for Mental ... will fund a new internship program that will enable students ...
... results from a large-scale Phase III trial of RTS,S*, published ... (NEJM), show the malaria vaccine candidate to provide young ... with an acceptable safety and tolerability profile. The results were ... & Melinda Gates Foundation in Seattle, Washington. Half the ...
Cached Medicine News:Health News:25 Deaths Now Blamed on Cantaloupe-Linked Listeria Outbreak 2Health News:Antineoplastic agents associated with thyroid dysfunction 2Health News:More evidence that allergies may help in fighting brain tumors 2Health News:Family and community medicine leader elected to Institute of Medicine 2Health News:Scott & White Healthcare is 1 of 3 in Texas to receive workforce development grants 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: